Back to Press Release List

Citrasate® at ERA-EDTA

May 12, 2004

BELLEVUE, Wash., USA – Advanced Renal Technologies (www.advrenaltech.com), developers of Citrasate® and DRYalysate® citric acid-based dialysate concentrates, announced today they will have exhibit booth 2.08b, adjacent to Fresenius, at the ERA-EDTA Annual Congress, May 15-18, 2004 in Lisbon, Portugal.

“ART is excited to be a part of Europe’s premier nephrology meeting,” said Mike Fulton, managing director. “As a developer of innovative technologies, ART relies on international meetings such as ERA-EDTA to make important contacts to partner with high quality manufacturers, distributors and academic partners throughout the world. We are keen to establish partnerships in Europe, Middle East, Asia and Latin America.”

Citrasate and DRYalysate are patented acid concentrates using citric acid, a known anticoagulant. ART’s citric acid-based dialysate concentrates are particularly helpful in better dialysis for those patients where heparin is contraindicated, such as heparin antibodies or allergies. The acid concentrate products are also helpful in acute dialysis where there is a risk of bleeding or clotting. Citrasate and DRYalysate have been shown to prevent dialyzer clotting, reduce metabolic acidosis and increase reuse of dialyzers.

Advanced Renal Technologies (ART) is focused on the development of novel and innovative therapeutics to improve the treatment of patients with acute and chronic kidney failure in hospital, home and outpatient dialysis facilities. More information about ART may be found at www.advrenaltech.com, or by contacting Mike Fulton at +1-425-453-8777.